Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy

被引：9

作者：

Chen, Man ^{[1
]}

Fu, Minjing ^{[1
]}

Wang, Aixian ^{[1
]}

Wu, Xueying ^{[1
]}

Zhen, Junyi ^{[1
]}

Gong, Meiwei ^{[1
]}

Zhang, Xian ^{[2
]}

Yue, Guanlan ^{[3
]}

Du, Qing ^{[1
]}

Zhao, Wei ^{[3
]}

Zhao, Yanli ^{[3
]}

Lu, Peihua ^{[3
]}

Wang, Hui ^{[1
]}

机构：

[1] Hebei Yanda Lu Daopei Hosp, Dept Lab Med, Sipulan Rd, Langfang 065201, Peoples R China

[2] Hebei Yanda Lu Daopei Hosp, Dept Haematol, Langfang, Peoples R China

[3] Hebei Yanda Lu Daopei Hosp, Dept Stem Cell Transplantat, Langfang, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 02期

关键词：

Chimeric antigen receptor T cells; allogeneic hematopoietic stem cell transplantation; refractory or relapsed B-cell lymphoblastic leukemia; flow cytometry; minimal residual disease; MINIMAL RESIDUAL DISEASE; CELL THERAPY; EXPRESSION; REMISSION;

D O I：

10.1080/10428194.2021.1980214

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Minimal residual disease (MRD) detection is an important prognostic parameter in patients with refractory or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). CD79a has been reported to exhibit a high degree of linage-specificity for B-cell differentiation, with a specificity of 88% and a sensitivity of 100%. In this study, we investigated the efficiency and prognostic role of cytoplasmic CD79a (cCD79a) antibody-gated multicolor flow cytometry (MFC) in MRD detection in patients with B-ALL who received CD19-targeted chimeric antigen receptor (CAR) T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT). The retrospective analysis was carried on to 59 patients who accepted allo-HSCT after CD19-CAR-T infusion from June 2016 to May 2017. The MFC MRD statuses before and after allo-HSCT were both strongly correlated with the transplantation prognosis, the MFC panel with cCD79a gating can effectively monitor MRD after CD19 CAR T-cell therapy and predict the prognosis after allo-HSCT.

引用

页码：426 / 434

页数：9

共 50 条

[1] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
Yang, Tingting
Dong, Yetian
Zhang, Mingming
Feng, Jingjing
Fu, Shan
Xiao, Pingnan
Hong, Ruimin
Xu, Huijun
Cui, Jiazhen
Huang, Simao
Wei, Guoqing
Chang, Alex H.
Huang, He
Hu, Yongxian
BLOOD, 2024, 144 : 2819 - 2819
[2] Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, Jae H.
Riviere, Isabelle
Gonen, Mithat
Wang, Xiuyan
Senechal, Brigitte
Curran, Kevin J.
Sauter, Craig
Wang, Yongzeng
Santomasso, Bianca
Mead, Elena
Roshal, Mikhail
Maslak, Peter
Davila, Marco
Brentjens, Renier J.
Sadelain, Michel
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (05): : 449 - 459
[3] Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
Li, Xin
Liu, Mei-Jing
Mou, Nan
Yang, Zhen-Xing
Wang, Jia
Mu, Juan
Zhu, Hai-Bo
Deng, Qi
ONCOLOGY LETTERS, 2021, 22 (05)
[4] Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
Liu, Sining
Zhang, Xinyue
Dai, Haiping
Cui, Qingya
Cui, Wei
Yin, Jia
Li, Zheng
Xue, Shengli
Yang, Chunxiu
Yang, Xiao
Qiu, Huiying
Miao, Miao
Chen, Suning
Jin, Zhengming
Fu, Chengcheng
Li, Caixia
Sun, Aining
Han, Yue
Wang, Ying
Yu, Lei
Wu, Depei
Tang, Xiaowen
BLOOD, 2021, 138
[5] CD19 CAR-T therapy and sepsis: dancing with the devil
Budde, Lihua E.
Zaia, John A.
BLOOD, 2018, 131 (01) : 7 - 8
[6] CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
Sun, Yao
Su, Yongfeng
Wang, Yizhi
Liu, Na
Li, Yuhang
Chen, Jianlin
Qiao, Zhuoqing
Niu, Jingwen
Hu, Jiangwei
Zhang, Bin
Ning, Hongmei
Hu, Liangding
FRONTIERS IN IMMUNOLOGY, 2021, 12
[7] Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia
Xian Zhang
Junfang Yang
Jingjing Li
Wenqian Li
Dan Song
Xin-an Lu
Fei Wu
Jianqiang Li
Dandan Chen
Xiangqun Li
Zhongwei Xu
Shuqiang Liu
Ziyu Li
Kui Ying
Peihua Lu
Cancer Immunology, Immunotherapy, 2022, 71 : 689 - 703
[8] Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia
Zhang, Xian
Yang, Junfang
Li, Jingjing
Li, Wenqian
Song, Dan
Lu, Xin-An
Wu, Fei
Li, Jianqiang
Chen, Dandan
Li, Xiangqun
Xu, Zhongwei
Liu, Shuqiang
Li, Ziyu
Ying, Kui
Lu, Peihua
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (03) : 689 - 703
[9] Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
Liu, Shuangyou
Deng, Biping
Yin, Zhichao
Lin, Yuehui
An, Lihong
Liu, Dan
Pan, Jing
Yu, Xinjian
Chen, Bingzhen
Wu, Tong
Chang, Alex H.
Tong, Chunrong
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 671 - 679
[10] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Wenjie Li
Lixia Ding
Wenhua Shi
Xinyu Wan
Xiaomin Yang
Jing Yang
Tianyi Wang
Lili Song
Xiang Wang
Yani Ma
Chengjuan Luo
Jingyan Tang
Longjun Gu
Jing Chen
Jun Lu
Yanjing Tang
Benshang Li
Journal of Translational Medicine, 21

← 1 2 3 4 5 →